A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 05 Aug 2019 Planned primary completion date changed from 28 Jun 2019 to 27 Mar 2020.
- 03 Apr 2019 Planned End Date changed from 27 Mar 2021 to 16 Apr 2021.
- 03 Apr 2019 Planned primary completion date changed from 6 Jun 2019 to 28 Jun 2019.